Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 16, 2021

SELL
$181.39 - $202.99 $319,609 - $357,668
-1,762 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $691,838 - $815,859
-3,690 Reduced 67.68%
1,762 $355,000
Q1 2021

May 06, 2021

BUY
$207.02 - $241.31 $224,616 - $261,821
1,085 Added 24.85%
5,452 $1.17 Million
Q4 2020

Feb 09, 2021

BUY
$207.01 - $276.09 $904,012 - $1.21 Million
4,367 New
4,367 $1.03 Million
Q1 2019

Apr 15, 2019

SELL
$163.73 - $194.7 $259,839 - $308,988
-1,587 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$151.91 - $192.21 $241,081 - $305,037
1,587 New
1,587 $263,000
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $259,646 - $298,361
-1,548 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$145.72 - $169.96 $225,574 - $263,098
1,548 New
1,548 $263,000
Q4 2017

Feb 01, 2018

SELL
$137.28 - $155.55 $340,454 - $385,764
-2,480 Closed
0 $0
Q3 2017

Oct 18, 2017

BUY
$148.13 - $162.24 $367,362 - $402,355
2,480
2,480 $377,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Quantitative Systematic Strategies LLC Portfolio

Follow Quantitative Systematic Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.